	US 12,263,162 B2
	Compositions, devices, and methods for treating or preventing headaches
John Kollins, San Francisco, CA (US); Fumiyoshi Iwashima, San Francisco, CA (US); Detlef Albrecht, Saratoga, CA (US); and Robert David Schultz, Raleigh, NC (US)
Assigned to SATSUMA PHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed by SATSUMA PHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed on Jul. 20, 2020, as Appl. No. 16/933,560.
Application 16/933,560 is a continuation of application No. 16/710,538, filed on Dec. 11, 2019, granted, now 10,758,532.
Claims priority of provisional application 62/847,607, filed on May 14, 2019.
Claims priority of provisional application 62/799,635, filed on Jan. 31, 2019.
Claims priority of provisional application 62/778,158, filed on Dec. 11, 2018.
Prior Publication US 2020/0345730 A1, Nov. 5, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61M 15/08 (2006.01); A61P 25/04 (2006.01)

CPC A61K 31/4985 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/14 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61M 15/08 (2013.01); A61P 25/04 (2018.01)]

25 Claims

1. A method for treating or preventing a headache, comprising administering to a human subject a powdery pharmaceutical composition that comprises 5 mg to about 7 mg of dihydroergotamine mesylate, and an excipient;

wherein said excipient comprises about 18 mg to about 19 mg of microcrystalline cellulose, and hydroxypropyl methylcellulose.